Logo

GSK Tests out Ambit s Profiling Technology

Mar 04, 2003

NEW YORK, March 4 - GlaxoSmithKline is evaluating Ambit Biosciences' screening technology to characterize small molecule kinase inhibitors, Ambit said today.

 

Since January, Ambit has been studying interactions between GSK's kinase inhibitors and proteins using its phage display-based screening approach.

 

Ambit Biosciences is based in San Diego.

Breaking News
The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.